ABSTRACT
Objective: To analyze the clinical characteristics, treatments, and outcomes of lung cancer patients with NTRK mutations. Methods: The clinical data of patients with pathologically confirmed primary lung cancer and the NTRK mutation in next-generation sequencing (NGS) admitted to Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology between October 2016 and November 2019 were retrospectively analyzed. The Kaplan-Meier method and the Log-rank test were used for the univariate survival analysis. Results: A total of 28 patients were enrolled. 27 patients were diagnosed as stage with point mutations or copy number amplifications of NTRK, and 1 patient was diagnosed as stage IIIC with AEN-NTRK3 (A1:N18) fusion. The univariate analysis showed that the median progression-free survival (PFS) was related to the pathological pattern (adenocarcinoma vs. squamous carcinoma: 9.4 months vs. 2.5months, P0.05, respectively). Contrastingly, the median PFS of EGFR-TKIs treatment for patients with EGFR mutant lung cancer and concomitant NTRK1 mutation was significantly longer than patients with concomitant NTRK3 mutation (12.4 months vs. 3.0 months, P<0.05). Conclusions: Patients with NTRK mutant lung adenocarcinoma had a longer PFS than patients with lung squamous carcinoma when they received first-line therapy. EGFR mutant patients with concomitant NTRK3 mutation had a poorer prognosis than patients with concomitant NTRK1 mutation when they received EGFR-TKIs treatment. Therefore, concomitant NTRK3 mutation may be one of the poor prognostic factors of EGFR mutant lung cancer.